---
title: "In the interim results, MS GROUP HLDGS reported a net profit of 15.55 million yuan, a decrease of 18%, and will not distribute dividends"
description: "MS GROUP HLDGS announced its interim results for the six months ended June, with revenue of HKD 181 million, an increase of 1.3% year-on-year. It recorded a net profit of HKD 15.55 million, a decline "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254311660.md"
published_at: "2025-08-24T09:06:27.000Z"
---

# In the interim results, MS GROUP HLDGS reported a net profit of 15.55 million yuan, a decrease of 18%, and will not distribute dividends

> MS GROUP HLDGS announced its interim results for the six months ended June, with revenue of HKD 181 million, an increase of 1.3% year-on-year. It recorded a net profit of HKD 15.55 million, a decline of 18%, with earnings per share of HKD 0.0775. No dividend was declared

MS GROUP HLDGS (01451.HK) announced its interim results for the six months ended June, with revenue of HKD 181 million, an increase of 1.3% year-on-year. It recorded a net profit of HKD 15.55 million, a decline of 18%, with earnings per share of HKD 0.0775. No dividend was declared

### Related Stocks

- [01451.HK - MS GROUP HLDGS](https://longbridge.com/en/quote/01451.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Hong Kong’s West Kowloon arts hub secures HK$3 billion, 10-year loan facility | The West Kowloon Cultural District Authority in Hong Kong has secured a HK$3 billion, 10-year loan from ICBC (Asia) to a | [Link](https://longbridge.com/en/news/275930491.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| Lenovo Caught Napping By 'Democratization Of AI' | Lenovo reported a 21% profit decline in its latest fiscal quarter, taking a $285 million restructuring charge due to a s | [Link](https://longbridge.com/en/news/275904944.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.